

Prior Authorization Request Form for Multiple Sclerosis Agent (Not for Tysabri or Zeposia)

FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720 OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

	i dutilorization may be complet	tea at meeps.//			in/prior dutilorization forms/	
I. PROVIDI	ER INFORMATION		II. MEMBER IN	NFORMATIO	ON CONTRACTOR OF THE PROPERTY	
Prescriber Na	rescriber Name:			Member Name:		
Prescriber Sp	rescriber Specialty:			Identification #:		
NPI:	PI:			Group #:		
Office Contact Name:			Date of Birth:			
Fax #:			Medication Allergies:			
Phone #:						
III. DRUG I	NFORMATION (One drug red	quest per forr	n)			
Drug name a	Drug name and strength: Dosage Interv		al (sig):		Qty. per Day:	
	RED DOCUMENTION (Detailed by the least of th			ition demon	strating evidence for each item	
Specify diagnosis & diagnosis code relevant to this request: Dx/Dx Code:						
progress	psing form of MS (specify) $\rightarrow \Box c$ sive disease	linically isolated	d syndrome □re	lapsing remit	ting disease □ active secondary	
☐ Has prin	mary progressive MS					
Does the me	mber have any contraindications	to the prescribe	ed medication?	☐ Yes ☐ No		
Requests for all non-preferred medications: Does the menhistory of trial and failure of or contraindication or intolerand preferred Multiple Sclerosis agents? Refer to https://papdl.ccdrug-list for a list of preferred and non-preferred medication. Does not apply to non-preferred brands when the therap equivalent generic is preferred or to non-preferred generated therapeutically equivalent brand is preferred.			ce to the om/preferred- s in this class. oeutically	□ Yes	Medications Previously Taken (start and end date and dose):	
speci □ Mem of usi □ If req Servi	specialist, please indicate a specialist consulted: Member has a current history (within past 90 days, or if greater than 90 days dosing interval is greater than 90 days) of using the prescribed the requested non-preferred multiple sclerosis agent, since:					
REQUEST FO Mem living REQUEST FO	g:OR MAVENCLAD (CLADRIBINE):	ER): ontinuous basis yte count within	s, impairing the ab		ete instrumental activities of daily — ng to FDA-approved package labeling	

RENEWAL REQUESTS FOR ALL: For Relapsing Form of MS, member has documented improvement or stabilizing of the multiple sclerosis disease course:							
For Primary Progressive MS, based on the prescriber agent		•					
☐ For Ampyra, member has improvement in motor fun RENEWAL REQUEST FOR LEMTRADA (ALEMTUZUMAB):	ction as evident by:						
☐ Received the previous treatment course at least RENEWAL REQUEST FOR MAVENCLAD (CLADRIBINE):	12 months prior to the requested treatment course						
☐ Member meets all the following: ☐ Has documentation of recent lymphocyte count version labeling before initiating the first treatment court		oved package					
☐ Has not exceeded the recommended total number	9 11	package labeling					
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :							
Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:					

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)